… Chlamydia pneumoniae, previously referred to as the TWAR … appear to have lower rates
of in-stent restenosis [89]. The … Sirolimus is a macrolide antibiotic which decreases levels of …

… growth inhibition of two chlamydial species, C. pneumoniae and Chlamydia trachomatis …
use, for example in mouthwashes for preventing pneumonia. Other non-antibiotic compounds …

… In-stent restenosis and neoatherosclerosis after … BBR (50 µmol/L) inhibited chlamydia
pneumoniae infection … that by inhibiting the activity of the mammalian target of rapamycin (mTOR) …

… an antimicrobial device and may lead to obscurity in labeling … Labeled use of sirolimus stents
does not include indications … the use of other preventive measures that may reduce the risk …

… that infectious agents like Chlamydia pneumoniae (Saikku et … proven efficacious with minimal
in-stent restenosis during a 6 … evoked in the recipient may contribute to the development of …

… hHSP)-60 and Chlamydia pneumoniae have been cloned from … Sirolimus has been shown
to decrease TEM circulating in the … , with a reduction of the in-stent restenosis rate Citation[38]. …

… shown evidence of Chlamydia pneumoniae within the plaque… as sirolimus and paclitaxel
can significantly retard in-stent … walking and rest causes partial denervation of limb muscles …

… Similarly, BBR attenuated Chlamydia pneumoniae infection-… /Akt/mammalian target of
rapamycin (mTOR) signaling pathway … in neovascular atherosclerosis and in-stent restenosis 94 . …

… in the development of restenosis after stent placement. … multifactorial processes such as
restenosis may decrease with the … of IL-1 antagonists as a preventive strategy against restenosis. …

… as well as for the design of preventive measures. Nonetheless, progress in improving … risk
of resistance development. Combinations of rifampicin with other antibiotics may in part derive …